Efficacy and Safety of Telitacicept in IgA Nephropathy and IgA Vasculitis-Associated Nephritis in Children: A Retrospective Single-Centre Study
Lanqi Zhou, Fengjie Yang, Yanxinli Han, Yuan Yang, Shi Yi Wu, Yu Zhang, Jianhua Zhou · 2025
Read Efficacy and Safety of Telitacicept in IgA Nephropathy and IgA Vasculitis-Associated Nephritis in Children: A Retrospective Single-Centre Study by Lanqi Zhou, Fengjie Yang, Yanxinli Han, Yuan Yang, Shi Yi Wu, Yu Zhang, Jianhua Zhou (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12717825.txt.
Description
Zhou and co-authors review their hospital's experience using telitacicept for childhood kidney disease in this 2025 study. The drug treats IgA nephropathy and IgA vasculitis kidney disease, two related conditions that remain hard for pediatricians. The study covered children with heavy protein in their urine.
Thirteen patients, seven with one disease and six with the other, received injections for at least six months. After six months, six of thirteen reached remission, four of them completely. Urine protein fell by a median of about 91 percent, and urine blood counts fell by about 96 percent. Kidney function stayed stable and normal. Antibody levels dropped significantly, matching the drug's immune-damping action.
Catalog record
| CREATOR | Lanqi Zhou, Fengjie Yang, Yanxinli Han, Yuan Yang, Shi Yi Wu, Yu Zhang, Jianhua Zhou |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |